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Abstract
Background Rectal cancer management has evolved into a complex multimodality approach with survival, local recurrence, and
quality of life parameters being the relevant endpoints. Surgical treatment for low rectal cancer has changed dramatically over the
past 100 years.
Discussion Abdominoperineal resection, once the standard of care for all rectal cancers, has become much less frequently
utilized as surgeons devise and test new techniques for preserving the sphincters, maintaining continuity, and performing
oncologically sound ultra-low anterior or local resections. Progress in rectal cancer surgery has been driven by improved
understanding of the anatomy and pathophysiology of the disease, innovative surgical technique, improved technology,
multimodality approaches, and increased appreciation of the patient’s quality of life. The patient with a low rectal cancer, once
almost universally destined for impotence and a colostomy, now has the real potential for improved survival, avoidance of a
permanent stoma, and preservation of the normal route of defecation.
Keywords Rectal cancer . Sphincter preservation . Total
mesorectal excision . Anterior resection . Intersphincteric
resection . Local excision rectal cancer
Historical Background
The modern era of rectal cancer surgery began with the descrip-
tion of the abdominoperineal resection (APR) byMiles in 1908.
Prior perineal and sacral approaches (e.g., Kraske approach) to
rectal cancer resection produced high rates of complications,
cancer recurrence, poor quality of life (QOL), and poor overall
survival. Miles’ operation reflected greater understanding of the
natural history of rectal cancer that was based on postmortem
examination of his patients after perineal resection. He observed
cancerous implants in the pelvic peritoneum, mesorectum, and
affected nodes of the left common iliac bifurcation. These
findings led him to develop a “cylindrical concept” of the spread
of rectal cancer to upward, downward, and lateral zones.1 The
original operation included resection of the rectum, sigmoid,
mesorectum, nodes of the iliac bifurcation, and a perineal com-
ponent to include the anus and levator ani muscles. Postopera-
tive mortality was high initially, but local recurrence decreased
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dramatically from 95 to 29 %.2 Subsequent improvements in
antisepsis, anesthesia, and postoperative care improved survival
significantly and made APR the gold standard operation for all
rectal cancers. Over time, various modifications were made in
patient positioning, perineal wound management, colostomy
creation, use of drains, and adjuvant therapy, but the ultimate
goal of the procedure, en bloc removal of the rectum with its
lymphovascular supply, remained unchanged.
Surgical progress in the twentieth century limited the APR
to cancers below the peritoneal reflection. Successful perfor-
mance of anterior resection for cancers of the middle and
upper rectum, as published by Claude Dixon in 19483 led to
the acceptance of this procedure and the creation of a “5 cm
rule” from the dentate line—reserving APR for cancers below
this level.
Improved understanding of cancer biology and surgical
technology has led surgeons to accept ever smaller distal
margins, which often translates into enhanced sphincter pres-
ervation rates. The oncologic and functional outcomes of
preserving intestinal continuity, however, continue to be a
matter of ongoing research and debate. Although an APR
remains the appropriate approach for many low rectal tumors,
the use of the procedure has steadily decreased over the last
four decades, particularly in specialized centers.4 In his classic
paper, Claude F. Dixon called the last 20 cm “the most
controversial segment of the large intestine… It is for this
region new procedures are constantly being advocated and
interest in old ones is being rekindled”.3 Over 60 years later,
his statement is still accurate, although perhaps most relevant
now to the distal-most 5 cm of the rectum.
Rationale for Sphincter-Sparing Techniques
Re-evaluation of the “5 cm rule” began in the 1980s and
1990s and the requisite length for distal resection margin
(DRM) began to shrink. Paralleling the systematic introduc-
tion of radiation or chemoradiation for stage II and III cancers,
the extent of the DRM was challenged by the recognition of
the importance of circumferential resection margin (CRM),
introduction of total mesorectal excision (TME) technique,
and adoption of the circular stapler which facilitated low
pelvic anastomoses. Williams et al. examined 50 potentially
curative APR specimens and found 90 % had no or <1 cm
distal intramural spread from the primary tumor.5 Further-
more, patients who did have intramural spread also had poorly
differentiated primary tumors and ultimately succumbed to
distant metastases. The authors concluded that rigid enforce-
ment of the “5 cm rule” provided little oncologic benefit,
especially in patients with adverse histologic features, while
at the same time negatively impacted QOL metrics. Other
studies confirmed that distal intramural spread of rectal cancer
was uncommon and likely associated with high grade tumors
and that survival was determined by metastatic disease rather
than local recurrence.6 A retrospective review of 334 patients
undergoing anterior resection with DRM <2, 2–5, or >5 cm
found no difference in local recurrence (7.3, 6.2, or 7.8 %,
respectively) or 5-year survival rates (69.1, 68.4, or 69.6 %).7
Similarly, Leo et al.8 found significant differences in survival
and recurrence between patients with positive and negative
DRMs, but no significant difference over 5 years between
patients with negative DRMs <1 and >1 cm. Evidence in
favor of smaller DRMs continued to accrue. A recent system-
atic review of 17 studies found no negative impact of DRM
<1 cm or even <5 mm in terms of local recurrence or overall
survival in patients with good risk tumors,9 supporting sphinc-
ter preservation even in very low tumors.
Reappraisal of the “5 cm rule” coincided with recognition
of the importance of the CRM and the description of TME.
Unacceptably high local recurrence rates after resection of
rectal cancer led to investigations of the role of CRM and its
correlation to local failure. Quirke and colleagues reviewed 52
rectal cancer specimens, finding lateral positive margins in
one quarter and local recurrence in more than 80 % of those
patients.10 Subsequent prospective studies confirmed the neg-
ative impact of positive CRM on recurrence and survival.11
Surgically, the CRMwas addressed by TME. Championed by
Heald, the concept of TME consisted of anatomically remov-
ing rectal cancers as a “tumor package” within the intact
mesorectal compartment as defined by an embryonic plane
between the parietal pelvic fascia and the visceral mesorectal
fascia (Fig. 1).12 Adoption of TME resulted in decreased
CRM positivity, decreased local recurrence, and increased
survival for rectal cancer patients. The rise in TME rates for
rectal cancers has coincided with a decrease in APR rates.
Surgical dissection along the “holy plane” extends to the
intersphincteric groove, allowing for dissection to the pelvic
floor and creation of very low anastomoses.13 Adoption of
TME in Sweden resulted in a fall in APR rates from 60 to
27 %, demonstrating the power of anatomical surgical tech-
nique in assuring an oncologically adequate dissection.14
Low anastomoses were facilitated not only by TME, but
also by the introduction of the circular stapler. Initially devel-
oped in Russia, improvement and acceptance of the device
allowed for low anastomoses to be performed more quickly
and easily. In 1980, Heald reported a drop in the annual
number of APRs performed from 27 to 4 in a single hospital
following adoption of the circular stapler.15 Tolerance of
smaller DRM, adoption of TME, and availability of circular
stapling devices have dramatically impacted APR rates. These
changes in approach to rectal cancer set the stage for new
techniques for sphincter preservation in low rectal cancers
including intersphincteric resection (ISR), perineal colostomy,
transanal TME, and the Anterior and Perineal PlanE for ultra-
low Anterior Resection of the Rectum (APPEAR) procedure
(see below). Over the course of the twentieth century, the
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quality benchmark in rectal cancer surgery has progressed
from the radical APR to the ability to preserve intestinal
continuity and function while achieving excellent oncologic
outcomes. APR can frequently be avoided if there is no
evidence for direct or indirect invasion (e.g., fistula formation)
of the pelvic floor and sphincter complex and in the hands of
an experienced surgeon has a high probability of achieving a
negative DRM and CRM.
Techniques for Sphincter Preservation
General Concepts
Successful resection of low rectal cancers is technically chal-
lenging. Important anatomic structures are seated deep within
the pelvis and can be difficult to see and access. Patient
characteristics, such as a narrow android pelvis or increased
visceral fat, provide additional challenges. Regardless of the
planned surgical approach, some assessments are broadly
applicable. Determination of patient fitness for an operation
and their preoperative continence may impact surgical op-
tions. Measurement of carcinoembryonic antigen (CEA)
should be performed. Cross-sectional imaging of the chest,
abdomen, and pelvis to assess for metastatic disease is stan-
dard, in addition to endoscopic clearance of the remainder of
the colon. Review of the anatomy and structures involved by
the tumor prior to the operation is essential. High quality rectal
cancer-specific MRI scans for local tumor and nodal staging,
in particular, can provide the surgeon with information on
CRM and for planning neoadjuvant treatment and the resec-
tion. In experienced hands, endorectal ultrasound (EUS), as an
alternative toMRI, can also provide local staging information,
but is not as useful for assessing CRM. If a stoma is planned or
considered, preoperative marking by the surgeon or enteros-
tomal therapist should be performed for optimal placement.
Use of infection-prevention measures and deep venous pro-
phylaxis is standard for these major procedures. In most cases,
the patient should be placed in stirrups intraoperatively to
allow access to both the abdomen and perineum. Attention
should be paid to positioning and padding the extremities in
order to prevent compression injuries to the peroneal nerves
and the brachial plexuses. Adequate lighting is crucial and
head lamps for the surgeon and assistant can be very useful.
Similarly, exposure is critical, and competent assistance, deep
retractors such as the St. Mark’s, and long instruments are
necessary. An extender for the electrocautery and an energy
sealing device are useful for hemostasis deep in the pelvis. If a
perineal portion is planned, synchronous abdominal and per-
ineal dissection by two surgical teams allows manipulation of
the tumor from above and below to achieve dissection in the
correct plane. Alternatively, the perineal dissection can be
completed in the prone position which may aid in exposure.
The perineal dissection can be the most complex portion of the
procedure, and transperineal or transrectal dissection
(discussed below) may assist the surgeon in achieving ade-
quate mesorectal resection for low tumors. Finally, the quality
of the surgical resection is an important determinant of local
recurrence and survival. Pathologic specimens should be eval-
uated and documented in a standardized fashion by both
surgeon and pathologist, paying special attention to the intact-
ness of the mesorectal envelope (Fig. 2).
Total Mesorectal Excision
Total mesorectal excision exploits an embryologic avascular
perimesorectal plane to extract a cylindrical specimen of rec-




Fig. 1 Appropriate planes for
total mesorectal excision. a
Anterior view demonstrating
dissection plane between visceral
mesorectal fascia and parietal
fascia. b Lateral view of
appropriate TME plane in the
male. c Lateral view of TME
dissection plane in the female
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vision is carried out in this areolar plane, maintained and
revealed by three-dimensional tension applied by the assistant.
Preservation of nerves critical for normal sexual and bladder
function is a hallmark of the technique. The technique of TME
has been described in detail16 and is summarized briefly here.
Following entry and exploration of the abdomen, mobilization
of the splenic flexure, proximal ligation of the colon, and high
ligation of the inferior mesenteric vessels, pelvic dissection
commences and proceeds circumferentially. Posteriorly, dis-
section is carried past the tip of the coccyx, completed by
sharp division of the rectosacral ligament. Lateral extension
carries the plane between the superior hypogastric plexus and
the mesorectum. As lateral dissection proceeds inferiorly,
meticulous maintenance of a plane between the increasingly
dense and adherent plexus and the mesorectum is required.
Straying medially from the plane in this region may compro-
mise the circumferential margin and produce bleeding from
mesorectal vessels; straying laterally may injure the nerves of
the hypogastric plexus and/or cause bleeding from the pelvic
sidewall. Following the plane anteriorly, dissection proceeds
through Denonvilliers’ fascia or the rectogenital septum be-
tween the mesorectum and prostate and seminal vesicles or
posterior wall of the vagina (Figs. 1b, c and 3a, b). Again, care
is required to avoid straying posteriorly compromising the
resection margin or anteriorly to avoid injury to the inferior
hypogastric plexus. Continued dissection circumferentially in
this plane (Fig. 3c) leads to the intersphincteric plane and a
clean muscle tube for distal transection.
Although never compared to traditional surgical ap-
proaches in a prospective, randomized fashion, TME dem-
onstrates clear superiority in terms of local recurrence and
survival as compared to historical controls. In 1998, Heald
and colleagues reported their experience with 519 patients,
few receiving adjuvant therapy. Their local recurrence rate
was 8 % and cancer-specific survival was 66 % at
10 years.17 These results represented a substantial improve-
ment over local recurrence rates of 30 % or higher in the
literature at the time. Reproduction of similar results in
other centers18 led to the acceptance of TME as the stan-
dard of care.
Function After Low Anterior Resection
While TME (commonly in conjunction with chemoradiation)
has had a significant impact on local recurrence rates of rectal
cancer, patients frequently experience varying degrees of al-
tered bowel function. Low anterior resection syndrome
(LARS) includes multiple bowel symptoms, may be associat-
ed with urinary or sexual dysfunction, varies in severity, and
may impact QOL. Patients report symptoms of urgency, in-
continence, and difficult evacuation at rates of 12–45, 10–71,
and 16–74 %, respectively.19 Some degree of improvement
with time is the norm, but symptoms can persist as late as
15 years postoperatively.20 Postoperative factors contributing
to the development of LARS include shortened intestinal
length and a diminished rectal reservoir as higher volumes
of more liquid stool are delivered to a smaller neorectum.
Anorectal manometry reveals reductions in urgent volume,
maximal tolerable volume, and rectal compliance.21 Other
factors contributing to the development of LARS include
damage to the sphincter complex or its innervation. Sympa-
thetic nerves are at risk during high ligation of the inferior
mesenteric artery (IMA), and parasympathetic nerves may be
injured when the surgeon attempts to obtain wide negative
CRMs. The levator ani nerve, arising from S3 and S4, runs on
the superior surface of the pelvic floor, making it vulnerable to
injury during dissection and potentially causing a dysfunc-




Fig. 2 Total mesorectal excision
specimen. a, b Gross view with
intact mesorectum without
“waisting” of the specimen. c Full
thickness cross sections following
fixation demonstrate a negative
circumferential resection margin.
Final pathology demonstrates a
1.5-cm T1 adenocarcinoma
arising in a 5.5-cm tubulovillous
adenoma
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Despite the increased focus on visualization and preserva-
tion of the pelvic autonomic nerve structures, symptoms con-
sistent with pelvic floor dysfunction are common following
TME. Of 178 participating patients with normal continence in
the Dutch TME trial, 69 (39 %) had new fecal incontinence
after rectal cancer treatment and 14 % had new onset com-
bined fecal and urinary incontinence.22 These troubling results
warrant further investigation. Although the percentage of pa-
tients with postoperative functional problems remains sub-
stantial, it is significantly reduced relative to functional out-
comes reported in the past. Today, functional outcome is
influenced through multiple factors, including the patient,
(neo) adjuvant therapy (radiation and chemotherapy toxicity),
surgical technique, and the method and level of anastomosis.
Intersphincteric Resection
Schiessel and colleagues described intersphincteric resection
(ISR) for rectal cancer in 1994.23 ISR exploits the plane
between smooth and striated sphincters to achieve a balance
between adequate oncologic resection and continence preser-
vation (Fig. 4). Proctectomy and TME are combined with
resection of all or part of the internal anal sphincter and
creation of a handsewn transanal anastomosis (Fig. 5).
The operation is carried out by abdominal and perineal
approaches. The abdominal approach consists of a proper
TME as described previously. The perineal approach then
allows for identification of the mass. Under direct vision, the
surgeon transects the internal sphincter 1 cm below the tumor.
The dissection is then carried cephalad to connect with the
TME plane developed transabdominally. As with all TME
procedures, a protective loop ileostomy is routinely construct-
ed. Laparoscopic24 and robotic25 approaches have been
described.
Intersphincteric resection is technically feasible because
the internal sphincter is a continuation of the rectal wall
(muscularis propria), which does not have mesorectum distal
to the levator ani muscles. Oncological outcomes, as with all
procedures, are dependent on proper patient selection. Onco-
logical concern related to the ISR stems from the possibility
that tumor extends beyond the intersphincteric plane into the
external sphincter, thus leading to a positive radial excision
margin—a circumstance that would likely require APR for
cure. Large series of patients undergoing ISR have been
published by American, European, and Asian groups.26 Re-
cently, a review of 14 high quality reports including over
1,200 patients was published.27 An R0 resection was achieved
in 97 % of patients with an average DRM of 1.7 cm and a
negative CRM in 96 %. Mean oncologic outcomes were
similar to initial reports but ranges varied widely. The overall
rate of local recurrence was 6.7 %, but ranged from 0 to 23 %.
Overall survival was 86.3 % (62–97 %) and disease-free
survival was 78.6 % (69–87 %).
Given that ISR removes all or part of the internal anal
sphincter, patients should be carefully informed in regard to
morbidity and functional outcomes following this procedure.
ISR should be reserved for young patients with strong preop-
erative sphincter pressures and long anal sphincters. An early
study by Shissel et al. reported satisfactory continence but
slightly higher recurrence rates.23 A follow-up study demon-
strated a 30-day morbidity of 7.7 % with 9.4 % developing a
A B
C
Fig. 3 Total mesorectal excision.
a Anterior dissection behind the
seminal vesicles. b Anterior
dissection in a female. c
Dissection in the “holy plane”
evidenced by an intact, shiny
mesorectum
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late coloanal stricture. Local recurrence rates were low at
5.3%, and mean overall survival was 126months. Continence
for flatus, liquid, and solid stool was maintained in 86 % of
patients at long-term follow-up. Frequency of defecation was
initially high, but dropped to slightly greater than 2/24 h after
6–12 months. Although continence results were acceptable,
symptom-specific QOL indices were significantly lower in
patients after ISR or coloanal anastomosis as compared to
patients after anterior resection.28
Lack of a standardized assessment instrument and incon-
sistent reporting of functional outcomes in recent, larger series
make consensus on functional outcome after ISR difficult. In a
review of eight studies reporting outcomes, 11–63 % of pa-
tients reported fecal soiling and 30–86 % reported perfect
continence27 with statistical assessment of the data showing
wide confidence intervals. The most likely interpretation of
the results is that functional outcome after ISR is highly
variable. Suggested modifications to the procedure to improve
A B
Fig. 4 Appropriate planes for
intersphincteric resection—TME
plane created from above
intersects intersphincteric plane. a




Fig. 5 Complete intersphincteric
resection. a Dissection begins at
the dentate line. b The rectum is
eviscerated through the anus after
joining of the abdominal and
perineal dissection planes. c
Handsewn coloanal anastomosis
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continence include a coloplasty29 or creation of a colonic
pouch. However, one study found the creation of a pouch to
be less critical for postoperative continence than tumor level
and height of the anastomosis.30 ISR, of necessity, interferes
with the mechanisms of continence and does not generate
perfect functional results. Difficulties include frequent defe-
cation, stool fragmentation, and incontinence. In considering
ISR, the surgeon and patient must consider the burden of these
symptoms versus the alternative, a permanent ostomy follow-
ing APR.
APPEAR
The Anterior Perineal PlanE for Ultra-low Anterior Resection
of the Rectum (APPEAR) technique is another recently de-
scribed method allowing very low rectal resection of rectal
cancer.31 A combined abdominal and perineal approach al-
lows access to low, difficult to access rectum between the
levator ani and the superior margin of the external anal
sphincter. Following transabdominal mobilization of the rec-
tum and transection of the rectosigmoid, a perineal wound is
created and a rectovaginal/rectrourethral plane developed and
carried upward to that created by the abdominal surgeon. This
approach spares the anal sphincter entirely yet it allows the
surgeon to dissect at least 2–3 cm lower than one could from
above. The rectum is freed laterally and posteriorly from the
perineal aspect and the specimen delivered through the peri-
neum (Fig. 6). A straight coloanal or a pouch anastomosis and
a protecting ostomy are created. An initial report of 14 patients
(seven with rectal neoplasia) described no mortality but sig-
nificant morbidity, with seven patients (50 %) developing
perineal infection and fistulae.31 No local recurrences were
appreciated, although one patient developed systemic disease.
The authors found a median Wexner continence score of 6
(range 0–8) after ileostomy closure and good QOL measures.
Compared to ultra-low anterior resection, the APPEAR
technique has the advantage of providing greater distal access
to the rectum for mobilization and, compared to ISR, has the
advantage of not disrupting the sphincters. However, a trou-
blesome perineal wound is created, and thus far, data on
oncologic outcomes are limited. Further time and study are
required to evaluate the promise of this technique.
Transanal TME
A second technique to improve perineal dissection and facil-
itate sphincter-sparing resection of ultra-low rectal tumors is
transanal TME, a natural orifice transluminal endoscopic sur-
gery (NOTES) approach to rectal cancer. International and
US32 case series have been reported. Transabdominal laparo-
scopic dissection is carried out in standard fashion following
TME principles. After placement of a purse-string suture in
the rectum >1 cm distal to the tumor, perineal dissection is
carried out transrectally via a multi-instrument port inserted in
the anus (Fig. 7). The specimen is extracted and anastomosis
created transanally. This approach also facilitates access to
rectal “no man’s land,” but compared to the APPEAR tech-
nique, has the advantage of not creating a separate perineal
wound. Report of 20 patients undergoing the procedure de-
scribed an average DRM of 2.6 cm and CRM of 1.8 cm.33 In
this series, 20 % of patients had complications: two with
urinary retention, one with ileus, and one with dehydration.
In total, 72 patients have been reported in the literature
(reviewed in34), but no long-term oncologic outcomes are
available. As with APPEAR, transanal TME has the potential
to improve the perineal aspect of the dissection and achieve a
sphincter-sparing R0 resection in more patients with low rectal
cancer, but further study is necessary to evaluate long-term
oncologic outcomes.
Local Excision
Selected Early Rectal Cancers May Be Managed with Local
Excision
Local excision of rectal cancer may be performed as definitive
therapy for selected early rectal cancers, in combination with
chemoradiotherapy for more advanced tumors, or as a pallia-
tive procedure for patients unable to undergo transabdominal
operation. Development of novel techniques such as transanal
endoscopic microsurgery (TEM) and transanal minimally in-
vasive surgery (TAMIS) underscores the enthusiasm for com-
plete avoidance of transabdominal surgery for rectal cancer.
However, the oncologic adequacy of these operations remains
a matter of study and debate. There is a lack of prospective,
randomized trials and published series vary in terms of patient
selection, adjuvant therapy, surgical technique, and length of
follow-up. Nonetheless, rates of local excision are
increasing35 and reflect the interest of patients and surgeons
in avoiding major, morbid operations for early stage disease.
Patient Selection
Regardless of surgical technique, appropriate patient selection
is the most critical and challenging element in achieving
adequate oncologic outcomes with local excision. Ideally,
tumors removed by local excision are node-negative, pT1
tumors with favorable histology, but none of those factors
may be determined with certainty preoperatively. Patients
selected for local excision should have small, mobile tumors
and EUS orMRI results suggesting the tumor is node negative
and confined to the bowel wall. Clinical exam and radiologic
studies provide important but imperfect data. Meta-analysis of
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endorectal ultrasound found a sensitivity and specificity of
73.2 and 75.8 % for lymph node involvement36 and 87.8 and
97.8 %, respectively, for staging T1 tumors.37 MRI specificity
was 75 % for tumor stage and 71 % for lymph node
involvement.38 A thorough workup cannot completely con-
firm that a tumor will be definitively treated with local
excision.
Postoperatively, pathological features determine whether
or not the patient is likely to have had adequate surgical
therapy or requires TME. Tumor characteristics including
size, depth of invasion, and lymphovascular invasion are
important determinants of local recurrence. Bach et al.39 ana-
lyzed 424 patients after TEM for rectal cancer and found that
93 % of patients with well to moderately differentiated pT1
A
B
Fig. 6 Perineal dissection in the
APPEAR technique. a Perineal
incision. b Evisceration of the
specimen through the perineal
wound after connection of




Fig. 7 Transanal TME. a
Dissection begins following the
placement of a purse string distal
to the tumor. b The posterior
mesorectum. c Dissection
posterior to the vagina
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tumors, <3 cm in diameter, without lymphovascular invasion,
with an R0 resection were free of recurrence at 36 months;
however, any violation of these qualities led to significantly
increased rates of recurrence. The authors concluded that local
excision ought to be considered compromise therapy or an
excisional biopsy for patients not meeting these characteris-
tics. Similarly, Borschitz et al. found that patients with high
risk T1 tumors, <1 mm margins, tumor fragmentation, or R1
resection had 49 % 10-year survival as compared to 89 %
among patients with low-risk tumors and R0 resection.
40 The
discovery of adverse pathologic characteristics after local
excision should be followed by immediate radical resection,
which may be performed without adverse oncologic outcome
compared to primary radical resection.41 However, even with
intensive surveillance, delaying TME until the clinical appear-
ance of recurrence has been shown to lead to significantly
worse rates of survival and resectability. Patients and surgeon
must be prepared for immediate TME after local excision if
tumor factors are less than ideal.
Surgical Technique
Standard transanal excision (TAE) is performed under general
or regional anesthesia, often with a pudendal block for anal-
gesia and sphincter relaxation. Retractors or an operating
anoscope is used for exposure, a headlamp for visualization,
and electrocautery, or other dissecting device, is used to excise
a full thickness section of the rectum. The tumor, attached
mesorectal fat, and a margin of normal tissue are removed.
The rectum is then closed transversely. Practical limits restrict
standard TAE to the low rectum.
TEM and TAMIS provide improved visualization and in-
strumentation allowing endoluminal excision higher in the
rectum. Dr. Gehard Buess of Germany developed and intro-
duced the TEM platform in the 1980s. The platform provides
rectal insufflation, 3D visualization andmagnification through
a stereoscope and binocular eyepiece, and instrumentation via
an operating rectoscope. TEM allows for full thickness resec-
tion in the extraperitoneal rectum, including perirectal fat and,
if necessary, circumferential resection and anastomosis
(Fig. 8). In the intraperitoneal rectum, mucosectomy is possi-
ble, but full thickness resection will cause loss of rectal insuf-
flation and possibly conversion to abdominal operation.
TAMIS, first described in 2009, is an alternative to TEM
for endoluminal resection of rectal lesions. Unlike TEM,
which requires specialized, proprietary instrumentation,
TAMIS is performed with instruments and techniques familiar
to the minimally invasive surgeon. A single incision laparo-
scopic surgery (SILS) apparatus or gel port-type device serves
in place of the TEM platform, and standard laparoscopic
surgical instruments are used. Relatively small case series
describe the safety and feasibility of TAMIS for resection of
adenomas and early rectal cancers,42 but the relative infancy
of the technique precludes long-term oncologic results at
present. TAMIS procedures in the upper rectum43 and in
combination with transabdominal TME for low rectal
cancers44 have been described.
Choice of Technique
Reported outcomes from local excision vary in terms of tech-
nique, (neo) adjuvant therapy, and length of follow-up. Few
prospective studies exist. After standard TAE, local recurrence
has been reported from 0 to 28 % for T1 tumors and overall
survival from 74 to 90 %.45 You et al.35 retrospectively com-
pared the outcomes of 2,124 patients reported to the National
Cancer Database and found significantly increased rates of
recurrence among patients undergoing local versus standard
excision of T1 rectal cancers (12.5 versus 6.9 %, p=0.003), but
on multivariate analysis, the type of surgery was not a signif-
icant predictor of 5-year overall survival. Local recurrence after
TEM has been reported from 0 to 11 % for good risk T1 rectal
tumors.46 The choice of TAE versus TEM is determined by
surgeon preference, equipment availability, and location in the
rectum. Tumors in the most distal 5 cm of the rectum can be
difficult to access with the TEMplatform. Retrospective review
of TAE versus TEM patients found increased rates of margin
positivity among patients excised with TAE versus TEM, but
found similar survival in both groups.47 Margin positivity, T
stage, distance from the anal verge, but not surgical approach
itself were predictors of local recurrence. Tumor factors and
quality of resection, therefore, are more important for patient
outcome than the operative approach. Proponents of TAMIS
argue that cost savings and a shorter learning curve are provid-
ed by the more familiar instrumentation. However, ex vivo data
suggests that some skills, such as endoscopic sewing, may be
more difficult in the TAMIS platform than in TEM.48 Further-
more, unlike TEM, a second operator is required to manipulate
the laparoscopic camera during TAMIS and TEM equipment
may still be necessary in challenging cases, precluding cost
savings. Since TAMIS was first described in 2009, no prospec-
tive trial comparing its outcomes to TAE or TEM approaches
has been completed.
Extended Indications for Local Excision
Neoadjuvant chemoradiotherapy can extend the utility of local
excision to T2N0 tumors. Equivalent disease-free survival at
5 years of follow-up was demonstrated in a randomized clin-
ical trial of chemoradiotherapy plus laparoscopic TME or
TEM in 100 patients with T2 rectal cancer.49 Although local
excision patients had shorter operations and hospitalizations
and were less likely to require blood transfusion, early post-
operative morbidity and rates of local recurrence and metas-
tasis were not significantly different between the two groups.
Other studies have shown equivalent rates of survival with
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increased rates of local recurrence among patients with T2N0
rectal cancer, although administration of (neo) adjuvant ther-
apy was not uniform in these retrospective studies.50
, 51 Sur-
geons and patients must remember that although chemoradio-
therapy may extend the indication for local excision to more
advanced tumors, it is not without functional consequences.
At 1 year after local excision and radiotherapy in a Polish
multicenter trial, patients had worse than expected anorectal
function, noting that 46 % of patients were incontinent to
loose stool and 21 % had significant detriment in global
QOL due to anorectal dysfunction. Anorectal functional out-
comes were similar to a control group that had undergone
anterior resection, although male sexual function was signif-
icantly better.52 These findings highlight the fact that anorectal
function is not solely dependent on surgical preservation of
nervous structures and that chemoradiotherapy is not a trivial
addition to patient functional outcome.
Multimodality Therapy and Sphincter Preservation
The goal of neoadjuvant chemotherapy in locally advanced
(pT3-T4) rectal cancer is tumor shrinkage—potentially
allowing for R0 resection and reduced rates of local and distant
recurrence. A role for neoadjuvant therapy in increasing rates
of sphincter preservation has been hypothesized, either by
increasing rates of anterior resection, altering the surgical
approach from radical resection to local excision, or adopting
a “watch and wait” nonsurgical approach to patients with a
complete response to therapy. The ideal regimen for neoadju-
vant therapy is a matter of study.53 In general, the radiotherapy
totals 45–50.4 Gy in 25–28 doses given concomitantly with
chemotherapy, which is typically 5-fluorouracil and
leucovorin. Other chemotherapy regimens continue to be
studied, but no alternative strategy has demonstrated superior
results. Surgery is then performed after several weeks, typi-
cally 6–8 weeks, although greater intervals may allow for
improved tumor response.54
It seems a forgone conclusion that if neoadjuvant therapy is
efficacious in tumor shrinkage, more patients presumed to
require APR would be able to undergo LAR, but data do not
support this hypothesis. One trial did demonstrate a 20 %
increase in the rate of anterior resection, but this finding was
seen only in subgroup analysis and important differences in
tumor characteristics were observed between nonradiated and
radiated groups.55 Meta-analyses of randomized trials, how-
ever, do not support increased rates of LAR after chemoradi-
ation. Review of 10 studies revealed no difference in rates of
LAR in patients with and without neoadjuvant therapy (p=
0.52).56 Similarly, a recent Cochrane review of six random-
ized trials found no effect of neoadjuvant therapy on the rate of
sphincter preservation.57 At present, the data do not support a
role for neoadjuvant therapy in increasing the rate of anterior
resection. Additionally, Heald and colleagues have demon-
strated an excellent rate of anterior resection (>90 %) with





Fig. 8 Full thickness local
excision of a rectal neoplasm
using TEM. a Dissection begins
with rectal lesion seen at the right.
b Dissection encompassing half
the circumference of the rectum,
nearly completed. cClosure of the
defect. d Resected specimen,
adenoma with a 2-mm focus of
T1 adenocarcinoma
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technique may play more of a role in avoiding APR than does
neoadjuvant therapy.
Patients do not respond uniformly to neoadjuvant chemora-
diation. An important minority of patients (8–24 %)58 have a
pathological complete response (pCR), with no viable cancer
cells in the resected specimen. Patients with pCR are a unique
subset with improved oncologic outcomes and the potential to
have organ or sphincter-sparing surgery. Pooled analysis of 484
of these patients from multiple studies revealed that these pa-
tients have reduced rates of local recurrence and better overall
survival.58
Patients with pCR are a subset of those with clinical com-
plete response (cCR). cCR is defined by the absence of
endoluminal irregularities on rectal exam or endoscopy, with
or without confirmatory radiologic findings on MRI, EUS, or
PET/CT. Determining which patients with a cCR also have a
pCR is difficult. Radiation-induced inflammation and fibrosis
in the rectum and mesorectum render both radiologic and
clinical exams unreliable. Many investigators therefore elect
to locally excise the previous tumor site after cCR and deter-
mine further therapy after re-staging. ypT0-T1 tumors are
significantly more likely to have node-negative disease that
ypT2-4 tumors (3 versus 39 %, p<0.0001)59 and have im-
proved rates of disease-free survival. Issa and colleagues60
described 20 patients treated with local excision and found to
have pCR. In this study, 49 % of patients with a cCR had a
ypT0 tumor at surgery, highlighting the less than perfect
predictive value of clinical response. However, ypT0 patients
had excellent results, with no recurrences at 87 months of
follow-up. Other authors have reported zero recurrence rates
for patients with significant downstaging treated with local
excision.61 While ypT0 tumors may be definitively treated by
local excision, the optimal management of patients with ypT1
or ypT2 disease may be proctectomy rather than local exci-
sion. Perez and colleagues described 33 patients with small
residual clinical disease resected with TEM after neoadjuvant
therapy. Fifteen percent recurred, exclusively within the ypT1-
T2 group. Disease-free survival at 12 months was 68 %.62
The Brazilian group led byHabr-Gama is at the forefront of
complete nonoperative management for cCR patients. Most
recently, they described 70 rectal cancer patients undergoing
neoadjuvant CRT: 54 Gy of radiation and 6 cycles of 5-FU/
leucovorin, with 68 % having a complete clinical response at
10 weeks following the completion of radiotherapy. These
patients were followed with clinical exam and either MRI or
PET/CT every 2 months for the first year, with less frequent
but regular follow-up thereafter. Patients without irregularities
were managed nonoperatively, those with subtle irregularities
underwent TEM, and those with pathologic or gross tumor
recurrence underwent radical surgery. At 1 year, 57 %
sustained complete response, and 51 % were free of recur-
rence at a median follow-up of 56 months.63 These results
indicate that a small, but important group of rectal cancer
patients with complete response to neoadjuvant therapy can
perhaps be managed nonoperatively, but these data need to be
replicated at other centers.
Neoadjuvant therapy is the standard of care for patients
with locally advanced rectal cancers. Selected patients with
excellent clinical or pathological response to neoadjuvant
therapy may be candidates for organ preservation within the
context of a highly rigorous follow-up program. However,
chemoradiation has not been proven to increase rates of ante-
rior resection or sphincter preservation among locally ad-
vanced rectal cancer patients as a group. Subject for ongoing
study and debate include predicting how tumors will respond
to neoadjuvant therapy, monitoring patients for response to
therapy, the optimal neoadjuvant regimen, and determining
the optimal treatment for patients with excellent, but incom-
plete, response to neoadjuvant therapy.
The Role of the APR in the Era of Sphincter-Saving
Techniques
The indications for APR have changed dramatically since it
was first described by Miles in the mid-twentieth century.
Sphincter preservation is now viewed as a mark of quality in
rectal cancer surgery. Oncologic outcomes, not just QOL
metrics, have also raised concerns that APR is an inferior
operation compared to anterior resection. Dissection close to
the rectum at the level of the puborectalis often creates a
specimen “waist” and yields positive CRMs. Pooled analysis
of 14 European rectal cancer studies found positive CRMs in
10 and 5 % of APR and anterior resection specimens,
respectively.64 Local recurrence rates were significantly ele-
vated (20 versus 11 %) and 5-year overall survival worse (59
versus 70 %) in patients with an APR as compared to an
LAR.64 These inferior outcomes in patients after APR could
be due to deficiencies in the surgical technique and/or tumor
characteristics. A review of 24 high quality studies found APR
to be associated with higher rates of CRM positivity and
tumor perforation and inferior oncologic outcomes, but also
found tumors in patients with APRs to be lower and more
locally advanced.65 Dramatic reduction in local recurrence
rates and margin positivity can be achieved by improving
and standardizing the perineal phase of surgery. Appropriate
extralevator resection planes follow the deep perineal fasica to
the levators which are then transected to connect with the
mesorectum (Fig. 9). As with transabdominal TME, care is
taken to avoid “waisting of the specimen.” Martijinse and
colleagues66 found that introduction of a quality improvement
program focusing on extralevator perineal dissection reduced
the rate of R1 resections of T4 tumors from 30.2 to 5.7 %.
Focus on performance improvement, improved imaging, and
adoption of neoadjuvant therapy on a national level in the
Netherlands have recently been shown to negate the difference
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in CRM positivity between LAR and APR in that country.67
Therefore, the patient requiring an APR, even for a locally
advanced tumor, may also have a comparable oncologic out-
come to a patient undergoing anterior resection.
Even in the era of sphincter-sparing surgery, APR is still the
operation of choice for patients with very low tumors or poor
preoperative function. Tumor characteristics necessitating an
APR include a T3 or T4 tumor in the anal canal or involving
the levator ani/external sphincter muscle. Patients with im-
paired continence; previous obstetric, traumatic, or iatrogenic
injury to the sphincters; or chronic diarrheal diseases such as
inflammatory bowel diseases are likely to do poorly following
creation of a low anastomosis. Patients should be counseled
about the likelihood of postoperative defecatory problems,
and any patient unable to accept these potential issues should
undergo APR. A patient’s preference for a stoma rather than
incontinence should certainly not be discounted, even in a
potential candidate for anterior resection.
Maintaining Intestinal Continuity After APR
Selected Patients Undergoing APRsMay BeAble toMaintain
Intestinal Continuity
Several authors have described restoration of intestinal continu-
ity following APR. Perineal colostomy, graciloplasty, and arti-
ficial sphincters provide pseudocontinence: intestinal continuity
is maintained, but antegrade or retrograde colonic enemas may
be required for defecation. Even though an immediate
reconstruction at the time of APR could technically be per-
formed, it is generally discouraged in favor of a secondary
approach after the oncological long-term goals have been met.
Parenthetically, the post-APR abdominoperineal reconstruction
is typically not covered by any insurance. Unlike ISR, for which
many large series are available for comparison, data on onco-
logic and functional outcomes for pseudocontinent procedures is
sparse, often limited to highly specialized centers.
One option for a perineal colostomy restores intestinal
continuity and creates pseudocontinence using a band of
autologous colonic tissue. Two centimeters proximal to the
skin, a 10-cm long strip of colonic tissue is folded on itself,
wrapped around the neorectum, and secured in order that this
band might provide a measure of continence for the perineal
colostomy. Colonic irrigations are performed for defecation.
Lasser and colleagues reported on 40 patients who underwent
this procedure following APR for rectal cancer.68 Morbidity
was high (55 %) with eight patients suffering perineal suppu-
ration. Four patients underwent conversion to colostomy—
two due to complications and two due to functional failures.
Of the remaining patients, only four were perfectly
continent.69 Comparison of small numbers of patients after
ISR (n=14) and after psuedocontinent perineal colostomy (n=
22) failed to find significant differences in QOL and conti-
nence between the two groups.70
Graciloplasty, either single or double, allows for the recon-
struction of a neosphincter followingAPR but is often followed
by muscle fatigue and poor function. Dynamic graciloplasty is
achieved by the inclusion of a subcutaneous pulse generator,





resection. a Anterior view
demonstrating abdominal
dissection in TME plane with
perineal specimen including
sphincter complex for a very low
rectal tumor. b Lateral view of
resection planes in the male. c
Lateral view of resection planes in
the female
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because of lack of FDA approval. As in patients whose
neosphincter was formed with autologous colonic tissues,
graciloplasty patients would need to perform colonic irrigation
with either retrograde or antegrade enemas (with the creation of
a Malone appendicostomy). A recent study of 10 patients
undergoing dynamic graci loplas ty with Malone
appendicostomy after APR reported high morbidity with
90 % requiring some type of reoperation.71 Despite the high
complication rates, many patients may ultimately achieve sat-
isfactory functional outcomes.72
A third described option to enhance function after APR is
through the use of the artificial bowel sphincter (ABS). The
ABS consists of a subcutaneous cuff surrounding the anus and
a pump in the labial or scrotal area. Patients are trained to
inflate and deflate the cuff in order to achieve defecation.
Report of eight patients undergoing ABS placement in a
synchronous or a delayed fashion after APR demonstrated
that, although a significant learning curve existed for the
patients, all but one were able to achieve a good continence
score.73 Three patients had early impaired defecation and one
suffered a wound infection.
Restoration of intestinal continuity after APR is a challenge
and the available procedures to achieve pseudocontinence are
limited by relatively little experience and, in some cases, high
rates of morbidity. However, these procedures may be appro-
priate for well-informed, highly motivated patients who are
not candidates for anterior or intersphincteric resection and
want to avoid a stoma at all costs.
Conclusion
Surgical therapy for rectal cancer has, over the past 100 years,
evolved from the radical operation of Miles to a number of
surgical options and novel techniques. These changes have
been driven by increased understanding of the pathophysiology
of rectal cancer, multimodality treatment, improved technology,
surgical innovation, and by surgeons placing greater emphasis
on the patient’s QOL. As a result of this progress, the postop-
erative patient with rectal cancer not only has an improved
chance of survival, but has real potential for continence and
normal sexual and urinary function. In the coming years, rela-
tively new procedures such as ISR, APPEAR, and transanal
TMEwill test the limits of what can be achieved with sphincter-
sparing resections for low rectal cancers, while advances in
multidisciplinary treatment may extend the ability of surgeons
to minimize surgical intervention. Regardless of technique,
however, the primary goal of surgical treatment of rectal cancer
remains oncologic cure, while preserving sphincter function
and maintaining intestinal continuity remain secondary goals.
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MOC Questions
1. Survival is most improved in patients with resectable rectal cancer by:
a. Administration of neoadjuvant chemoradiotherapy
b. Removing a specimen with a 2 cm distal resection margin
c. Surgical resection with total mesorectal excision
d. APR for tumors <5 cm from the dentate line
2. After anterior resection, anorectal function:
a. Is uniformly poor
b. Is typically unchanged from pre-operative baseline
c. Is entirely dependent on preservation of sympathetic nerves
d. Depends on patient factors, surgical technique, and (neo)-adjuvant
therapy
3. Local excision for rectal cancer:
a. May be appropriate for selected good risk tumors
b. Is only adequate when TEM equipment is employed
c. Accurately stages rectal cancer
d. Is less frequently performed now than in prior years
4. Compared to ISR and transanal TME, the APPEAR technique is
unique in that it:
a. Has superior long term outcomes
b. Creates a perineal wound
c. Facilitates resection of very low rectal tumors
d. Allows for total mesorectal excision
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